Olix Pharmaceuticals Overview
- Year Founded
-
2010
- Status
-
Public
- Employees
-
67
- Stock Symbol
-
226950
- Investments
-
3
- Share Price
-
$56.08
- (As of Monday Closing)
Olix Pharmaceuticals General Information
Description
OliX Pharmaceuticals Inc is a clinical stage biotechnology company. It is engaged in developing RNA interference (RNAi) technology therapeutics for dermal, ophthalmic and pulmonary diseases. The company's pipeline products include OLX101, OLX201, OLX301, OLX102, and others.
Contact Information
Website
www.olixpharma.comCorporate Office
- 953 Daewangpangyo-ro
- Sujeong-gu
- Seongnam, Gyeonggi 13106
- South Korea
Corporate Office
- 953 Daewangpangyo-ro
- Sujeong-gu
- Seongnam, Gyeonggi 13106
- South Korea
Olix Pharmaceuticals Timeline
Olix Pharmaceuticals Stock Performance
As of 16-Nov-2026, Olix Pharmaceuticals’s stock price is $56.08. Its current market cap is $1.28B with 22.8M shares.
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $56.08 | $60.63 | $50.59 - $146.56 | $1.28B | 22.8M | 228K | -$0.39 |
Olix Pharmaceuticals Financials Summary
As of 30-Jun-2026, Olix Pharmaceuticals has a trailing 12-month revenue of $9.4M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 2,061,906 | 1,890,014 | 250,324 | 190,660 |
| Revenue | 9,396 | 10,306 | 4,161 | 13,052 |
| EBITDA | (8,780) | (7,046) | (25,078) | (10,175) |
| Net Income | (9,668) | (11,062) | (29,799) | (14,610) |
| Total Assets | 177,617 | 135,670 | 48,371 | 79,791 |
| Total Debt | 13,493 | 16,171 | 26,608 | 30,541 |
Olix Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Olix Pharmaceuticals Comparisons
Industry
Financing
Details
Olix Pharmaceuticals Competitors (78)
One of Olix Pharmaceuticals’s 78 competitors is Redx Pharma, a Venture Capital-Backed company based in Macclesfield, United Kingdom.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Redx Pharma | Venture Capital-Backed | Macclesfield, United Kingdom | ||||
| Fate Therapeutics | Formerly VC-backed | San Diego, CA | ||||
| Beam Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| Immunocore Holdings | Formerly VC-backed | Abingdon, United Kingdom | ||||
| Sarepta Therapeutics | Formerly VC-backed | Cambridge, MA |
Olix Pharmaceuticals Patents
Olix Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026054553-A1 | Double-stranded rna for innate immune response-based anticancer therapy, and use thereof | Pending | 06-Sep-2024 | ||
| WO-2026049536-A1 | Rnai agent targeting apoc3 gene and use thereof | Pending | 30-Aug-2024 | ||
| WO-2024210530-A1 | Rnai agents targeting lpa gene and use thereof | Inactive | 03-Apr-2023 | ||
| WO-2024186166-A1 | Double-stranded rna having innate immune response-inducing effect, and use thereof | Inactive | 08-Mar-2023 | ||
| AU-2024232235-A1 | Rnai formulation for prevention or treatment of obesity and combination therapy using same | Pending | 08-Mar-2023 | A61P3/04 |
Olix Pharmaceuticals Signals
Olix Pharmaceuticals Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Olix Pharmaceuticals Investments (3)
Olix Pharmaceuticals’s most recent deal was a PIPE with PCL for . The deal was made on 12-Dec-2022.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| PCL | 12-Dec-2022 | PIPE | Other Healthcare Technology Systems | ||
| Golf Korea (957.6 Square Meters of Land Property in Seongnam, South Korea) | 29-Dec-2021 | Corporate Asset Purchase | Buildings and Property | ||
| Sungkyunkwan University (Patent Right for Nucleic Acid Molecules Inducing RNA Interference) | 30-Aug-2018 | Corporate Asset Purchase | Buildings and Property |
Olix Pharmaceuticals ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
39.45 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Pharmaceuticals
Subindustry
of 354
Rank
Percentile
Olix Pharmaceuticals FAQs
-
When was Olix Pharmaceuticals founded?
Olix Pharmaceuticals was founded in 2010.
-
Where is Olix Pharmaceuticals headquartered?
Olix Pharmaceuticals is headquartered in Seongnam, South Korea.
-
What is the size of Olix Pharmaceuticals?
Olix Pharmaceuticals has 67 total employees.
-
What industry is Olix Pharmaceuticals in?
Olix Pharmaceuticals’s primary industry is Drug Discovery.
-
Is Olix Pharmaceuticals a private or public company?
Olix Pharmaceuticals is a Public company.
-
What is Olix Pharmaceuticals’s stock symbol?
The ticker symbol for Olix Pharmaceuticals is 226950.
-
What is the current stock price of Olix Pharmaceuticals?
As of 16-Nov-2026 the stock price of Olix Pharmaceuticals is $56.08.
-
What is the current market cap of Olix Pharmaceuticals?
The current market capitalization of Olix Pharmaceuticals is $1.28B.
-
What is Olix Pharmaceuticals’s current revenue?
The trailing twelve month revenue for Olix Pharmaceuticals is $9.4M.
-
Who are Olix Pharmaceuticals’s competitors?
Redx Pharma, Fate Therapeutics, Beam Therapeutics, Immunocore Holdings, and Sarepta Therapeutics are some of the 78 competitors of Olix Pharmaceuticals.
-
What is Olix Pharmaceuticals’s annual earnings per share (EPS)?
Olix Pharmaceuticals’s EPS for 12 months was -$0.39.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process